Interleukin-4 Modulates the Inflammatory Response in Ifosfamide-Induced Hemorrhagic Cystitis
- 314 Downloads
We investigated whether interleukin-4 (IL-4) is present and capable of reducing inflammatory changes seen in ifosfamide-induced hemorrhagic cystitis. Male Swiss mice were treated with saline or ifosfamide alone or ifosfamide with the classical protocol with mesna and analyzed by changes in bladder wet weight (BWW), macroscopic and microscopic parameters, exudate, and hemoglobin quantification. In other groups, IL-4 was administered intraperitoneally 1 h before ifosfamide. In other experimental groups, C57BL/6 WT (wild type) and C57BL/6 WT IL-4 (−/−) knockout animals were treated with ifosfamide and analyzed for changes in BWW. Quantification of bladder IL-4 protein by ELISA in control, ifosfamide-, and mesna-treated groups was performed. Immunohistochemistry to tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) as well as protein identification by Western blot assay for inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) was carried out on ifosfamide- and IL-4-treated animals. In other experimental groups, antiserum against IL-4 was given 30 min before ifosfamide. In IL-4-treated animals, the severity of hemorrhagic cystitis was significantly milder than in animals treated with ifosfamide only, an effect that was reverted with serum anti-IL-4. Moreover, knockout animals for IL-4 (−/−) exhibit a worse degree of inflammation when compared to C57BL/6 wild type. Exogenous IL-4 also attenuated TNF-α, IL-1β, iNOS, and COX-2 expressions in ifosfamide-treated bladders. IL-4, an anti-inflammatory cytokine, attenuates the inflammation seen in ifosfamide-induced hemorrhagic cystitis.
KEY WORDSIL-4 ifosfamide bladder hemorrhagic cystitis TNF-α IL-1β iNOS COX-2
The authors gratefully acknowledge the technical assistance of Maria Silvandira Freire, José Ivan Rodrigues, and Jand Venes Medeiros from FM-UFC-CE and Arturo Rivera from University of Miami, USA and also would like to thank the National Research Council of Brazil (CNPq) and Fundação Cearense de Amparo a Pesquisa (FUNCAP), Ceará-Brazil, for the financial support.
This project has received grants from National Research Council of Brazil (CNPq), CAPES, and Fundação Cearense de Amparo à Pesquisa (FUNCAP), Ceará-Brazil.
Conflict of Interests
- 9.Ribeiro, R.A., H.C. Freitas, M.C. Campos, et al. 2002. Tumor necrosis factor-α and interleukin-1 β mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. Journal d’Urologie 176: 2229–2234.Google Scholar
- 10.Souza-Filho, M.V.P., M.V.A. Lima, M.M.L. Pompeu, et al. 1997. Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. The American Journal of Pathology 150: 247–256.Google Scholar
- 14.Vannier, E., M.C. Miller, and C.A. Dinarello. 1992. Coordinated anti-inflammatory effects of interleukin4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proceedings of the National Academy of Science 89: 4076–4080.CrossRefGoogle Scholar
- 15.Seitz, M., P. Loetscher, B. Dewald, H. Towbin, M. Ceska, and M. Baggiolini. 1994. Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes-regulation by IFN-γ and IL-4. Journal of Immunology 152: 2060–2065.Google Scholar
- 16.Endo, T., F. Ogushi, and S. Saburo. 1996. LPS-dependent cyclooxygenase-2 induction in human monocytes is down-regulated by IL-13, but not by IFN-γ. Journal of immunology 156: 2240–2246.Google Scholar
- 18.Gray, K.J., U.H. Engelmann, E.H. Johnson, et al. 1986. Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. Journal d'Urologie 133: 497–500.Google Scholar
- 20.Fenton, M.J., J.A. Buras, and R.P. Donelly. 1992. IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes. Journal of Immunology 149: 1283–1288.Google Scholar
- 23.Trepicchio, W.L., M. Bozza, G. Pedneault, and A.J. Dorner. 1996. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. Journal of Immunology 157: 3627–3634.Google Scholar